NCT06280378View on ClinicalTrials.gov

Β-Thalassemia Treatment with KL003 Cell Injection

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 5, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

May 31, 2027

Conditions
Transfusion-dependent Beta-Thalassemia
Interventions
DRUG

KL003 Cell Injection Drug Product

Administered by intravenous infusion after myeloablative conditioning with busulfan.

Trial Locations (2)

Unknown

RECRUITING

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Kanglin Biotechnology (Hangzhou) Co., Ltd.

INDUSTRY